Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04594681
Other study ID # 4951-001
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date September 16, 2020
Est. completion date August 26, 2022

Study information

Verified date May 2023
Source Kyowa Kirin Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate safety and tolerability after administration of KHK4951 in healthy volunteers and patients with wet age-related macular degeneration.


Recruitment information / eligibility

Status Terminated
Enrollment 116
Est. completion date August 26, 2022
Est. primary completion date August 26, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: Healthy Volunteers - Voluntary written informed consent to participate in the study - Japanese or white men 20 to < 50 years at the time of informed consent - BMI 18.5 to < 30.0 at screening - Intraocular pressure (study eye) 10.0 mm Hg to 21.0 mm Hg - Monocular or binocular visual acuity (corrected visual acuity if correction is required) = 1.0 at screening Inclusion Criteria: Patients - Voluntary written informed consent to participate in the study - Age = 50 years at the time of informed consent - AMD-associated by active subfoveal CNV lesions in the study eye or juxtafoveal CNV lesions with CNV-associated findings in the fovea in the study eye - CST = 300 µm in the study eye at screening, as measured by OCT - BCVA score = 23 letters in the study eye at screening and enrollment, as measured by the ETDRS visual acuity chart - BCVA score = 58 letters in the non-study eye at screening, as measured by the ETDRS visual acuity chart - In subjects with prior treatment of the study eye with anti-vascular endothelial growth factor (anti-VEGF) drugs such as Beovu, Eylea, Lucentis, Avastin, or Macugen, presence of response to the anti-VEGF drug(s) as judged by the investigator or subinvestigator based OCT, FA, visual acuity, or other assessment results Exclusion Criteria: Healthy Volunteers - Current illness requiring treatment - History of ophthalmologic laser surgery, ophthalmologic surgery, nasolacrimal duct surgery, orany eyelid surgery affecting flow in the nasolacrimal duct - History of or current circulatory disease (e.g., cerebrovascular or cardiovascular disease) - History of or current dry eye - Abnormal findings on OCT at screening or enrollment examination Exclusion Criteria: Patients - Clinical findings or a history of conditions other than wAMD affecting the retina and choroid (e.g., diabetic retinopathy, diabetic macular edema, myopic CNV, retinal vein occlusion, or premacular membrane) in either of the eyes - Any of the following diseases in the study eye: - Glaucoma - Ischemic optic neuropathy - Retinitis pigmentosa - Current or history of vitreous hemorrhage or macular hole in the study eye - Any abnormality in the anterior segment of the eye or vitreous body that may affect fundus observation by OCT, color fundus photography, or fluorescein angiography

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Placebo is administered once daily or three times daily.
KHK4951
KHK4951 is administered once daily or three times daily.

Locations

Country Name City State
Japan Hakata clinic Fukuoka

Sponsors (1)

Lead Sponsor Collaborator
Kyowa Kirin Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with adverse events For adverse events that occurred after administration of the investigational drug, number of subjects with AEs and occurrence frequency are evaluated. Day 1 to Day 43
Secondary Serum KHK4951 concentration Healthy Volunteers: Day 1, Day2, Day4, Day8, Day12, Day16, Day21, Day23, Day 25, Day 29, Day 36, Day 43; Patients: Day 1, 8, 22, 43
Secondary Time to the maximum concentration Day 1 to Day 43
Secondary The maximum concentration Day 1 to Day 43
Secondary Area under the concentration-time curve Day 1 to Day 43
Secondary Apparent clearance Day 1 to Day 43
Secondary Elimination half-life Day 1 to Day 43
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1